Skip to main content

Advertisement

Table 1 Disease indications with greater than 5% of specimens showing high TMB (>20 mutations/Mb)

From: Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Disease type Specimen count Median mutations/Mb Percentage cases with >20 mutations/Mb (95% CI)
Skin basal cell carcinoma 92 47.3 70.7 (60.7–79)
Skin squamous cell carcinoma (SCC) 266 45.2 67.3 (61.4–72.7)
Skin melanoma 879 14.4 39.7 (36.4–42.9)
Skin merkel cell carcinoma 206 4.3 37.9 (31.5–44.7)
Unknown primary melanoma 1324 12.6 37.6 (35–40.2)
Head and neck melanoma 59 6.3 25.4 (14.7–36)
Lung large cell carcinoma 74 12.2 24.3 (14.9–33.7)
Unknown primary squamous cell carcinoma (SCC) 606 7.6 21.6 (18.4–24.9)
Lung large cell neuroendocrine carcinoma 288 9.9 19.8 (15.6–24.8)
Lung sarcomatoid carcinoma 130 7.2 19.2 (12.7–26)
Stomach adenocarcinoma intestinal type 58 5.0 19 (10.9–30.9)
Uterus endometrial adenocarcinoma endometrioid 459 4.5 18.5 (15–22.1)
Lymph node lymphoma diffuse large B cell 348 10.0 18.4 (14.7–22.8)
Lung non-small cell lung carcinoma (NOS) 2636 8.1 17 (15.6–18.5)
Unknown primary sarcomatoid carcinoma 64 5.4 15.6 (7.6–24.6)
Unknown primary malignant neoplasm (NOS) 491 3.8 14.9 (12–18.3)
Uterus endometrial adenocarcinoma (NOS) 743 4.5 14.7 (12.3–17.4)
Bladder carcinoma (NOS) 77 8.1 14.3 (8.2–23.8)
Unknown primary urothelial carcinoma 188 7.2 13.8 (9.2–18.9)
Soft tissue angiosarcoma 157 3.3 13.4 (8.9–19.6)
Lung adenocarcinoma 11855 6.3 12.3 (11.7–12.9)
Lung adenosquamous carcinoma 154 5.4 12.3 (7.5–17.7)
Skin adnexal carcinoma 74 3.6 12.2 (6.5–21.5)
Bladder urothelial (transitional cell) carcinoma 1218 7.2 11.9 (10.1–13.8)
Lymph node lymphoma B-cell (NOS) 88 6.3 11.4 (6.3–19.7)
Lung squamous cell carcinoma (SCC) 2102 9.0 11.3 (10–12.7)
Unknown primary carcinoma (NOS) 1405 4.5 10.7 (9.2–12.4)
Head and neck squamous cell carcinoma (HNSCC) 1184 5.0 10.1 (8.5–11.9)
Lung small cell undifferentiated carcinoma 913 9.9 9 (7.3–11)
Nasopharynx and paranasal sinuses squamous cell Carcinoma (SCC) 67 4.5 9 (4.2–18.2)
Ovary endometrioid adenocarcinoma 105 3.6 8.6 (4.6–15.5)
Unknown primary undifferentiated small cell carcinoma 117 6.3 8.5 (4.1–14)
Brain oligodendroglioma 321 2.7 8.4 (5.6–11.6)
Small intestine adenocarcinoma 277 4.5 8.3 (5.3–11.7)
Soft tissue malignant peripheral nerve sheath tumor (MPNST) 134 2.5 8.2 (4.1–13.2)
Soft tissue sarcoma undifferentiated 260 2.5 8.1 (5.3–12)
Uterus endometrial adenocarcinoma clear cell 62 3.6 8.1 (3.5–17.5)
Prostate undifferentiated carcinoma 91 3.6 7.7 (3.8–15)
Salivary gland mucoepidermoid carcinoma 55 2.7 7.3 (2.9–17.3)
Unknown primary adenocarcinoma 2751 3.6 6.9 (6–7.9)
Ureter urothelial carcinoma 88 5.4 6.8 (2.5–12.6)
Cervix squamous cell carcinoma (SCC) 284 5.4 6.7 (4.3–10.2)
Penis squamous cell carcinoma (SCC) 60 4.5 6.7 (2.6–15.9)
salivary gland carcinoma (NOS) 160 3.6 6.3 (3.4–11.1)
Kidney urothelial carcinoma 224 5.4 6.3 (3.8–10.2)
Unknown primary undifferentiated neuroendocrine carcinoma 674 2.7 6.1 (4.5–8.1)
Duodenum adenocarcinoma 249 3.6 6 (3.4–9.2)
  1. CI confidence interval, NOS not otherwise specified